Key financial ranges
Market cap · USD equivalent
P/E ratio
Annual revenue · USD equivalent
Revenue growth
Valuation & profitability
Price / sales
Annual net income · USD equivalent
Net profit margin
Cash & debt
Cash · USD equivalent
Total debt · USD equivalent
Net cash · USD equivalent
Debt / revenue
| Company | Market cap | P/E | Revenue | Rev. growth | Net income | Cash | Debt | AI value |
|---|---|---|---|---|---|---|---|---|
| RLJRLJ Lodging Trust | $1.68B | 1,860.2× | $1.35B | -1.4% | $28.51M | $937.6M | $2.81B | Undervalued |
| OBKOrigin Bancorp, Inc. | $1.68B | 17.1× | $390.83M | +9.9% | $75.2M | $546.53M | $57.59M | Fair valued |
| GLOBGlobant S.A. | $1.69B | 15.3× | $2.45B | +1.6% | $103.96M | $243.74M | $473.65M | Undervalued |
| NVAXNovavax Inc | $1.69B | — | $1.12B | +64.7% | $440.3M | $191.46M | $297.32M | Fair valued |
| PLABPhotronics Inc | $1.69B | 10.1× | $849.29M | -2.0% | $136.41M | $511.49M | $3.85M | Undervalued |
| QCRHQcr Holdings Inc | $1.69B | 12.2× | $369.54M | +6.4% | $127.19M | $111.34M | $8.91M | Fair valued |
| RBCAARepublic Bancorp Inc | $1.69B | 14.8× | $417.5M | +8.5% | $131.32M | $354.09M | $30.08M | Fair valued |
| IDTIdt Corp | $1.7B | 20.9× | $1.23B | +2.1% | $76.09M | $214.96M | $1.38M | Fair valued |
| HUNHuntsman CORP | $1.7B | — | $5.68B | -5.8% | -$284M | $369M | $2.49B | Fair valued |
| LILALiberty Latin America Ltd. | $1.7B | — | $4.44B | -0.1% | -$611.2M | $714.1M | $8.96B | Fair valued |
| LINDLindblad Expeditions Holdings, Inc. | $1.7B | — | $771.02M | +19.6% | -$29.72M | $318.89M | $665.56M | Overvalued |
| ATEXAnterix Inc. | $1.7B | 24.8× | $6.5M | +7.8% | $90.64M | $116.01M | $4.09M | Fair valued |
| HAWKHawkEye 360, Inc. | $1.7B | — | $117.66M | +74.2% | $10 | $503.36M | $16.68M | Fair valued |
| CBLCbl & Associates Properties Inc | $1.7B | 8.0× | $16.24M | -12.5% | $135.97M | $101.28M | $2.03B | Fair valued |
| TYRATyra Biosciences, Inc. | $1.71B | — | — | — | — | $73.84M | $5.58M | Overvalued |
| UROYUranium Royalty Corp. | $1.71B | 194.2× | $186.81M | +1,566.0% | $40.25M | $241.96M | $114K | Overvalued |
| SEPNSepterna, Inc. | $1.71B | — | $45.95M | +4,174.5% | -$48.88M | $84.66M | $22.55M | Overvalued |
| AGROAdecoagro S.A. | $1.72B | 37.2× | $1.52B | +16.9% | $92.1M | $340M | $1.61B | Fair valued |
| DMRADamora Therapeutics, Inc. | $1.72B | — | — | — | — | $540.52M | $68K | Overvalued |
| CASHPathward Financial, Inc. | $1.72B | 10.4× | $839.89M | +5.3% | $185.87M | $149.41M | $223.77M | Fair valued |